Rochester, Minnesota




S. Jeson Sangaralingham, Ph.D., M.S., is a translational cardiovascular investigator who studies biological mechanisms and signaling cascades that contribute to adverse cardiorenal fibrosis, remodeling and failure. His primary focus is on the protective role of the natriuretic peptide-particulate guanylyl cyclase-cyclic guanosine monophosphate (NP-pGC-cGMP) system. Using this scientific knowledge, Dr. Sangaralingham and his team are leading efforts to discover, engineer and develop innovative drugs that enhance the protective actions of the pGC-cGMP system for cardiorenal diseases such as heart failure, ischemic heart disease, hypertension and chronic kidney disease.

Dr. Sangaralingham is also committed to identifying novel plasma and urinary natriuretic-based biomarkers for use in diagnosis and prognosis of cardiorenal disease. His investigational techniques include pGC-cGMP-targeted drug discovery (peptide and small molecule based) and engineering, in vitro biomolecular studies in human primary cell lines, in vivo experimental animal models of human cardiorenal disease including organ function and tissue analysis, and human population studies including natriuretic-based biomarker discovery and proof-of-principle clinical trials. He has a number of issued and pending patents worldwide and his research program is funded by the National Institutes of Health.

Focus areas

  • Natriuretic peptide and small-molecule-based drug discovery, design and development
  • Cardiorenal fibrosis, remodeling and failure
  • Cardiorenal protection
  • Pathophysiology of cardiorenal diseases such as heart failure, ischemic heart disease, hypertension and chronic kidney disease
  • Natriuretic peptide-based plasma and urinary biomarkers to identify and track cardiorenal injury and disease as well as predict clinical outcomes

Significance to patient care

Dr. Sangaralingham's translational cardiovascular research program is of great clinical impact, as the burden of cardiorenal disease worldwide is significant. He is highly focused on transforming scientific ideas and discoveries at the bench into novel therapeutic, diagnostic and prognostic strategies at the bedside, with goals of reducing the burden of cardiorenal disease and improving the quality of life for patients.

Professional highlights

  • Principal investigator, R01 grants awarded from the National Heart, Lung, and Blood Institute and National Institute on Aging
  • Associate director, Discovery, National Institutes of Health Cardiovasology Program
  • Fellow, American Heart Association
  • Recipient, Scientist Development Grant, American Heart Association
  • Recipient, Career Development Award in Cardiovascular Research, St. Jude Medical
  • Recipient, Jay N. Cohn New Investigator Award, Clinical/Integrative Physiology, Heart Failure Society of America


Primary Appointment

  1. Associate Consultant II, Division of Circulatory Failure, Department of Cardiovascular Medicine

Administrative Appointment

  1. Associate Consultant II-Research, Department of Physiology & Biomedical Engineering

Academic Rank

  1. Associate Professor of Medicine
  2. Associate Professor of Physiology


  1. Postdoctoral Research Fellowship - Cardiovascular Disease Mentor: John C. Burnett Jr., MD Division of Cardiovascular Diseases, Cardiorenal Research Laboratory
  2. Observership - Echocardiography Lakeridge Health Center
  3. Observership - Echocardiography London Cardiac Institute
  4. PhD - Cardiovascular Science, Anatomy & Cell Biology Queen's University
  5. MS - Cardiovascular Science, Anatomy & Cell Biology Queen's University
  6. BSc (Hons) - Life Science Queen's University

Clinical Studies

Learn about clinical trials that address specific scientific questions about human health and disease.

Explore all research studies at Mayo Clinic.


See the peer-reviewed findings I have published as a result of my research.

Review publications.

Mayo Clinic Footer